These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 7873459)

  • 1. Intravenous pamidronate: infusion rate and safety.
    Tyrrell CJ; Collinson M; Madsen EL; Ford JM; Coleman T
    Ann Oncol; 1994; 5 Suppl 7():S27-9. PubMed ID: 7873459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of pamidronate in the management of bone metastases from breast cancer: results of a non-comparative multicenter phase II trial. Aredia Multinational Cooperative Group.
    Tyrrell CJ
    Ann Oncol; 1994; 5 Suppl 7():S37-40. PubMed ID: 7532992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pamidronate in the treatment of bone metastases: results of 2 dose-ranging trials in patients with breast or prostate cancer.
    Lipton A; Glover D; Harvey H; Grabelsky S; Zelenakas K; Macerata R; Seaman J
    Ann Oncol; 1994; 5 Suppl 7():S31-5. PubMed ID: 7532991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study.
    Glover D; Lipton A; Keller A; Miller AA; Browning S; Fram RJ; George S; Zelenakas K; Macerata RS; Seaman JJ
    Cancer; 1994 Dec; 74(11):2949-55. PubMed ID: 7525038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens.
    Conte P; Guarneri V
    Oncologist; 2004; 9 Suppl 4():28-37. PubMed ID: 15459427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal safety of 1-hour pamidronate infusion for breast cancer and multiple myeloma patients: comparison between clinical trials and population-based database.
    de Lemos ML; Taylor SC; Barnett JB; Hu F; Levin A; Moravan V; O'Reilly SE
    J Oncol Pharm Pract; 2006 Dec; 12(4):193-9. PubMed ID: 17156591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone.
    Gucalp R; Theriault R; Gill I; Madajewicz S; Chapman R; Navari R; Ahmann F; Zelenakas K; Heffernan M; Knight RD
    Arch Intern Med; 1994 Sep; 154(17):1935-44. PubMed ID: 8074597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.
    Hortobagyi GN; Theriault RL; Porter L; Blayney D; Lipton A; Sinoff C; Wheeler H; Simeone JF; Seaman J; Knight RD
    N Engl J Med; 1996 Dec; 335(24):1785-91. PubMed ID: 8965890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous pamidronate in patients with tumor-induced osteolysis: a biochemical dose-response study.
    Body JJ; Dumon JC; Piccart M; Ford J
    J Bone Miner Res; 1995 Aug; 10(8):1191-6. PubMed ID: 8585422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of pamidronate in patients with renal failure and hypercalcemia.
    Machado CE; Flombaum CD
    Clin Nephrol; 1996 Mar; 45(3):175-9. PubMed ID: 8706358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
    Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
    J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases.
    Cremers SC; Papapoulos SE; Gelderblom H; Seynaeve C; den Hartigh J; Vermeij P; van der Rijt CC; van Zuylen L
    J Bone Miner Res; 2005 Sep; 20(9):1543-7. PubMed ID: 16059626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study.
    von Moos R; Caspar CB; Thürlimann B; Angst R; Inauen R; Greil R; Bergstrom B; Schmieding K; Pecherstorfer M
    Ann Oncol; 2008 Jul; 19(7):1266-1270. PubMed ID: 18334511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
    Ibrahim A; Scher N; Williams G; Sridhara R; Li N; Chen G; Leighton J; Booth B; Gobburu JV; Rahman A; Hsieh Y; Wood R; Vause D; Pazdur R
    Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomized, multicenter phase III trial.
    Conte PF; Giannessi PG; Latreille J; Mauriac L; Koliren L; Calabresi F; Ford JM
    Ann Oncol; 1994; 5 Suppl 7():S41-4. PubMed ID: 7873461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term renal safety profile of ibandronate 6 mg infused over 15 minutes.
    von Moos R; Caspar CB; Steiner R; Angst R; Inauen R; Schmieding K; Thürlimann B
    Onkologie; 2010; 33(8-9):447-50. PubMed ID: 20838060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pamidronate distribution in pediatric renal and rheumatologic patients.
    Acott PD; Wong JA; Crocker JF; Lang B; O'Regan P; Renton KW
    Eur J Clin Pharmacol; 2006 Dec; 62(12):1013-9. PubMed ID: 17024486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women.
    Boonen S; Sellmeyer DE; Lippuner K; Orlov-Morozov A; Abrams K; Mesenbrink P; Eriksen EF; Miller PD
    Kidney Int; 2008 Sep; 74(5):641-8. PubMed ID: 18509324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ; Mancini I
    Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged administration of bisphosphonates is well-tolerated and effective for skeletal-related events in Chinese breast cancer patients with bone metastasis.
    Ding X; Fan Y; Ma F; Li Q; Wang J; Zhang P; Yuan P; Xu B
    Breast; 2012 Aug; 21(4):544-9. PubMed ID: 22627092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.